In This Article:
As global markets navigate the complexities of tariff uncertainties and mixed economic indicators, major indices like the S&P 500 have experienced slight declines, while manufacturing activity shows signs of recovery. In this environment, high growth tech stocks that demonstrate resilience to geopolitical tensions and adaptability to evolving market conditions can be particularly appealing for investors seeking opportunities in a rapidly changing landscape.
Top 10 High Growth Tech Companies
| Name | Revenue Growth | Earnings Growth | Growth Rating |
|---|---|---|---|
| Seojin SystemLtd | 35.41% | 39.86% | ★★★★★★ |
| Clinuvel Pharmaceuticals | 21.39% | 26.17% | ★★★★★★ |
| eWeLLLtd | 26.41% | 28.82% | ★★★★★★ |
| Yggdrazil Group | 30.20% | 87.10% | ★★★★★★ |
| Pharma Mar | 23.24% | 44.74% | ★★★★★★ |
| Medley | 20.95% | 27.32% | ★★★★★★ |
| Mental Health TechnologiesLtd | 25.83% | 113.12% | ★★★★★★ |
| JNTC | 29.48% | 104.37% | ★★★★★★ |
| Dmall | 29.53% | 88.37% | ★★★★★★ |
| Delton Technology (Guangzhou) | 20.25% | 29.52% | ★★★★★★ |
Click here to see the full list of 1212 stocks from our High Growth Tech and AI Stocks screener.
Let's explore several standout options from the results in the screener.
Planisware SAS
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Planisware SAS is a business-to-business software-as-a-service provider with operations across Europe, North America, the Asia-Pacific, and other international markets, and has a market capitalization of €2.02 billion.
Operations: Planisware SAS generates revenue primarily through its software and programming segment, amounting to €170.48 million. As a business-to-business software-as-a-service provider, it serves various international markets.
Planisware SAS, with its enterprise-wide solutions like the recent adoption by Northrop Grumman, demonstrates robust integration into significant industrial operations, enhancing its market stance. Despite a competitive software sector, Planisware's revenue and earnings growth at 14.7% and 18.4% respectively outpace the French market averages of 5.8% and 12.5%, highlighting its strong performance niche. The company's commitment to innovation is evident in its R&D expenditure trends, ensuring it remains at the forefront of technological advances within program management systems.
-
Dive into the specifics of Planisware SAS here with our thorough health report.
-
Assess Planisware SAS' past performance with our detailed historical performance reports.
EuBiologics
Simply Wall St Growth Rating: ★★★★★☆
Overview: EuBiologics Co., Ltd. is a biopharmaceutical company that specializes in providing vaccines for epidemics in South Korea, with a market capitalization of ₩416.49 billion.
Operations: EuBiologics focuses on the biopharmaceutical sector, generating revenue primarily from its pharmaceuticals segment, which amounts to ₩69.37 billion.